The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Private Equity | Alive

Total Raised


Last Raised

$6.3M | 5 yrs ago

About GEN1 Biotechnology

GEN1 Biotechnology is a biopharmaceutical manufacturer.

GEN1 Biotechnology Headquarter Location

Adelaide, South Australia,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GEN1 Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GEN1 Biotechnology is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest GEN1 Biotechnology News

GEN1 Biotechnology Raises AUD$8m USD$6.3m

Aug 10, 2017

Biotechnology Stocks Repligen Major Breakout Funds were raised from Australian private equity investors, local banks, and the South Australian Government’s Health Industries Fund. GEN1 is building Australia’s first large-scale pharmaceutical factory manufacturing high-value injectable biopharmaceuticals for the Australian and international markets. GEN1 Chief Financial Officer, Kishen Vijayadass, is buoyant about the funding announcement. “This round of funding will support the company’s delivery of a factory in Adelaide that will benefit all Australians,” Mr Vijayadass said. “Adelaide has a vibrant, fast-growing life sciences community and the South Australian Government, through Health Industries South Australia, was very responsive to GEN1 and provided invaluable support.” Chief Executive of Health Industries South Australia Marco Baccanti said GEN1 will be a boon for South Australia and its health system. “According to GEN1, it has the potential to save South Australia up to $70m a year in medication spending”, Mr Baccanti said. “GEN1 will be in a great position to provide high-quality cost-effective products, and it will be doing so locally, right here in Adelaide.” Health Industries South Australia attracted GEN1 to Adelaide by helping the company to establish and secure a government partnership, including a grant from the Health Industries Fund. GEN1 raised its initial funding from Asian and European investors. This latest round of AUD$8m (USD$6.3m) comes after the company set up its initial operations in Adelaide. GEN1 will raise a total of AUD$160m (USD$126m) over the next three years. The company secured a site in Adelaide’s Tonsley Innovation District, located just 20 minutes south of the CBD, allowing ease of access for employees and to critical infrastructure, such as Adelaide Airport. GEN1’s factory will be the first of its kind and scale in Australia, manufacturing injectable medicines that are currently imported. Medications will include treatment for chronic conditions such as cancer, hypertension and diabetes. According to IMS Health, the market for injectable medication in Australia is larger than AUD$10 billion (USD$7.9b) a year with an estimated growth of 15-20% a year. Health Industries South Australia is an agency of the South Australian Government, which helps health and life sciences companies to locate and grow in Adelaide. View source version on Media Contact

  • Where is GEN1 Biotechnology's headquarters?

    GEN1 Biotechnology's headquarters is located at Adelaide.

  • What is GEN1 Biotechnology's latest funding round?

    GEN1 Biotechnology's latest funding round is Private Equity.

  • How much did GEN1 Biotechnology raise?

    GEN1 Biotechnology raised a total of $6.3M.

  • Who are the investors of GEN1 Biotechnology?

    Investors of GEN1 Biotechnology include Government of South Australia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.